Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NLM001 + zalifrelimab
- Development stage
- Unknown
- Lead developer
- Nelum
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
NLM001 + zalifrelimab is an investigational combination therapy being developed by Nelum Corp in collaboration with Agenus for the treatment of first-line advanced pancreatic cancer. The regimen consists of NLM001 (also known as NLM-001), a small-molecule Hedgehog pathway inhibitor, and zalifrelimab (AGEN1884), a monoclonal antibody that acts as a CTLA-4 antagonist. NLM001 is designed to target cancer-associated fibroblasts within the tumor microenvironment, thereby promoting immune cell infiltration and improving the penetration of co-administered chemotherapy. Zalifrelimab serves as a checkpoint inhibitor to enhance the anti-tumor immune response. This combination is currently being evaluated alongside standard-of-care chemotherapy in the Phase 1/2 NUMANTIA clinical trial (NCT04827953).
- Other names
- NLM001 + zalifrelimabNLM-001 + zalifrelimab
02
Targets
SMO (Smoothened)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)
Beyond the preview
Go deeper on NLM001 + zalifrelimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NLM001 + zalifrelimab.